Key result
Poliovirus developed complete resistance to the host-targeting antiviral drug Brefeldin A through point mutations in viral proteins 2C and 3A, allowing replication to high titers.
Poliovirus can escape inhibition by the antiviral drug Brefeldin A through mutations in viral proteins 2C and 3A, demonstrating the plasticity of host-virus interactions.
Resistance to host-targeting antivirals can emerge via viral mutations; leaves open durability of such strategies against RNA viruses.
Viral replication depends on specific interactions with host factors. For example, poliovirus RNA replication requires association with intracellular membranes. Brefeldin A (BFA), which induces a major rearrangement of the cellular secretory apparatus, is a potent inhibitor of poliovirus RNA replication. Most aspects governing the relationship between viral replication complex and the host membranes remain poorly defined. To explore these interactions, we used a genetic approach and isolated BFA-resistant poliovirus variants. Mutations within viral proteins 2C and 3A render poliovirus resistant to BFA. In the absence of BFA, viruses containing either or both of these mutations replicated similarly to wild type. In the presence of BFA, viruses carrying a single mutation in 2C or 3A exhibited an intermediate-growth phenotype, while the double mutant was fully resistant. The viral proteins 2C and 3A have critical roles in both RNA replication and vesicle formation. The identification of BFA resistant mutants may facilitate the identification of cellular membrane-associated proteins necessary for induction of vesicle formation and RNA replication. Importantly, our data underscore the dramatic plasticity of the host-virus interactions required for successful viral replication.
No takes yet. Share an insight, caveat, or question.
Crotty et al. (2004) studied Poliovirus infection. Brefeldin A vs. No Brefeldin A was evaluated on Viral replication (PFU/ml). Poliovirus developed complete resistance to the host-targeting antiviral drug Brefeldin A through point mutations in viral proteins 2C and 3A, allowing replication to high titers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: